M&A / Deals Autoimmune disease biotech Odyssey sets terms for $225m IPO PharmaphorumAfter abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.Immunology & InflammationRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cytospire hauls in $83M for a new type of T cell engagerNext: Latus Bio secures $97m in funding to boost gene therapy access Related Stories M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026 M&A / Deals GBL joins CVC in 10.7bn takeover bid for Recordati pharminent May 22, 2026 M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn pharminent May 22, 2026
